Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the...
“Let’s start with something simple. I cannot recall a time this year when it feels this good to be diversified among a whole host of terrific...
It was another month of gains for the stock market, even as Wall Street had to navigate a barrage of uncertainty. Since the Investing Club’s last...
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images WeightWatchers’ CEO said on Wednesday it...
Traders work on the floor of the New York Stock Exchange (NYSE) on Nov. 12, 2025 in New York City. Spencer Platt | Getty Images The...
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading...
Investors should take advantage of the volatility in artificial intelligence stocks and scoop up shares at a discount, according to portfolio manager Tom Hancock. Hancock, who...
Novo Nordisk has a lot on its plate — and it may not all be healthy. The pharmaceutical giant pulled out of its bidding war against...
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. 1....
Multiple waves of obesity treatment adoption should drive Eli Lilly higher from here, according to Leerink Partners. The investment firm upgraded the biopharmaceutical stock to outperform...
